Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALB | P02768 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086587 | 0.87 | LMNA (0.52) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL6394877 | 0.87 | LMNA (0.52) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL14664273 | 0.86 | LMNA (0.53) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL14664272 | 0.86 | LMNA (0.53) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL14664299 | 0.86 | LMNA (0.53) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL23882937 | 0.84 | LMNA (0.51) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL13389887 | 0.84 | LMNA (0.51) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL13390019 | 0.84 | LMNA (0.51) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL13389809 | 0.84 | LMNA (0.51) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL8583379 | 0.84 | LMNA (0.51) | TK1LMNAALBBLMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093737-A1 | Nucleoside and Nucleotide Analogues with Quaternary Carbon Centers and Methods of Use | INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093737-A1 | Nucleoside and Nucleotide Analogues with Quaternary Carbon Centers and Methods of Use | NUDT1, NT5C3B, NTPCR | TK1 32/4885LMNA 1497/4885ALB 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.